METHYCLOTHIAZIDE Drug Patent Profile

Which patents cover Methyclothiazide, and when can generic versions of Methyclothiazide launch?

Methyclothiazide is a drug marketed by Chartwell Rx, Ivax Pharms, Mylan, Par Pharm, Pharmobedient, Usl Pharma, and Watson Labs. and is included in fifteen NDAs.

The generic ingredient in METHYCLOTHIAZIDE is deserpidine; methyclothiazide. There are four drug master file entries for this compound. Additional details are available on the deserpidine; methyclothiazide profile page.

Summary for METHYCLOTHIAZIDE

US Patents:	0
Applicants:	7
NDAs:	15

US Patents and Regulatory Information for METHYCLOTHIAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	METHYCLOTHIAZIDE	methyclothiazide	TABLET;ORAL	089835-001	Aug 18, 1988		DISCN	No	No
Par Pharm	METHYCLOTHIAZIDE	methyclothiazide	TABLET;ORAL	089136-001	Feb 12, 1986		DISCN	No	No
Ivax Pharms	METHYCLOTHIAZIDE	methyclothiazide	TABLET;ORAL	087786-001	May 18, 1982		DISCN	No	No
Watson Labs	METHYCLOTHIAZIDE	methyclothiazide	TABLET;ORAL	085476-001	Mar 11, 1982		DISCN	No	No

Methyclothiazide: Patent Landscape and Commercial Outlook

Last updated: February 19, 2026

Methyclothiazide, a thiazide diuretic, is protected by expired patents, allowing for generic competition. Its established efficacy in treating hypertension and edema underpins continued market presence. Investment considerations center on manufacturing efficiency, market penetration strategies for generic formulations, and potential for combination therapies.

What is the patent status of methyclothiazide?

All primary patents covering the composition of matter and initial manufacturing processes for methyclothiazide have expired. The U.S. Patent and Trademark Office (USPTO) lists original patents for thiazide diuretics, including methyclothiazide, as having expired decades ago. For instance, foundational patents for thiazide compounds were granted in the late 1950s and early 1960s. Specific patents such as U.S. Patent 2,807,620, filed in 1956, cover the broad class of benzothiadiazine 1,1-dioxides, of which methyclothiazide is a member. These patents expired by the late 1970s or early 1980s.

The absence of active patent protection for the active pharmaceutical ingredient (API) allows any manufacturer meeting regulatory standards to produce and market generic versions of methyclothiazide. This has resulted in a competitive market dominated by multiple generic manufacturers. Secondary patents related to specific formulations, extended-release mechanisms, or novel delivery systems may exist but are not readily apparent in publicly accessible patent databases as major market drivers for the immediate product. Analyzing these secondary patents would require a deep dive into specific product claims by individual generic companies.

What are the key therapeutic indications for methyclothiazide?

Methyclothiazide is primarily indicated for the management of hypertension and the treatment of edema. Its mechanism of action involves inhibiting sodium and chloride reabsorption in the distal convoluted tubule of the nephron, leading to increased excretion of sodium, chloride, and water. This diuresis reduces extracellular fluid volume, thereby lowering blood pressure and alleviating edema.

• Hypertension: Methyclothiazide is used as a monotherapy or in combination with other antihypertensive agents to control elevated blood pressure. It is particularly effective in managing mild to moderate hypertension.
• Edema: The drug is prescribed to reduce fluid retention associated with conditions such as congestive heart failure, liver cirrhosis, and renal disease.

The therapeutic profile is well-established, with efficacy demonstrated through numerous clinical studies over several decades. Its role in hypertension management is often as a first-line agent or as part of a multi-drug regimen.

Who are the major manufacturers and market participants for methyclothiazide?

The market for methyclothiazide is characterized by the presence of numerous generic pharmaceutical manufacturers. Due to patent expiry, competition is driven by manufacturing cost, supply chain efficiency, and market access. Key players in the generic pharmaceutical space are likely to be involved in the production and distribution of methyclothiazide.

Companies such as:

• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (now Viatris Inc.)
• Sandoz (a division of Novartis AG)
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.

These companies, along with other global generic manufacturers, produce and distribute methyclothiazide in various dosage forms, most commonly as oral tablets. The market share is fragmented, with individual companies holding smaller portions rather than a dominant position. Pricing is highly competitive.

What is the global market size and growth potential for methyclothiazide?

The global market for methyclothiazide is a subset of the broader diuretic and antihypertensive drug market. As a mature, off-patent drug, its market size and growth are modest. Precise figures for methyclothiazide alone are difficult to isolate due to its inclusion in broader market reports. However, the global diuretic market is estimated to be in the billions of U.S. dollars annually, with thiazide diuretics representing a significant portion.

The growth potential for methyclothiazide is constrained by several factors:

• Competition from newer antihypertensives: The development of newer drug classes with potentially improved efficacy, tolerability, or specialized indications has shifted prescribing patterns.
• Price sensitivity: The generic nature of methyclothiazide leads to intense price competition, limiting revenue growth.
• Stable demand: While its indications remain relevant, the demand is largely stable, driven by the prevalence of hypertension and cardiovascular diseases.

Growth is primarily driven by:

• Increasing prevalence of hypertension: Global demographic trends, including aging populations and rising rates of obesity, contribute to a growing patient pool requiring antihypertensive treatment.
• Market penetration in emerging economies: Expansion of healthcare access and pharmaceutical markets in developing countries can create incremental demand for established generics.
• Combination therapy formulations: The development and marketing of fixed-dose combination products that include methyclothiazide with other antihypertensive agents can sustain or slightly increase its market presence.

Estimates suggest the market for generic diuretics, including methyclothiazide, will see a Compound Annual Growth Rate (CAGR) of 3-5% in the coming years, largely driven by volume increases rather than price appreciation [1].

What are the key regulatory considerations for methyclothiazide manufacturing and sales?

Manufacturing and selling methyclothiazide are subject to stringent regulatory oversight by health authorities worldwide. The primary regulatory body in the United States is the Food and Drug Administration (FDA), and in Europe, it is the European Medicines Agency (EMA).

Key regulatory considerations include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to current GMP regulations to ensure the consistent quality, safety, and efficacy of the drug product. This includes controls over raw materials, manufacturing processes, facility maintenance, and personnel training.
• Abbreviated New Drug Application (ANDA): For generic versions in the U.S., manufacturers must file an ANDA with the FDA, demonstrating bioequivalence to the reference listed drug (RLD). This involves comparative pharmacokinetic and/or pharmacodynamic studies.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies, containing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
• Pharmacovigilance: Post-market surveillance for adverse events is mandatory. Manufacturers must have systems in place to monitor, report, and manage any safety concerns.
• Labeling and Packaging: Product labeling must comply with regulatory requirements, accurately reflecting indications, contraindications, warnings, precautions, dosage, and administration. Packaging must ensure product stability and prevent contamination.
• Quality Control Testing: Rigorous quality control testing of both the API and the finished dosage form is required to confirm identity, purity, potency, and dissolution characteristics.

Compliance with these regulations is essential for market access and continued sales. Failure to adhere can result in warning letters, import alerts, product recalls, and market withdrawal.

What is the competitive landscape and pricing strategy for generic methyclothiazide?

The competitive landscape for methyclothiazide is highly fragmented and price-sensitive. With no patent protection for the API, multiple manufacturers vie for market share based on cost-effectiveness and distribution networks.

Key competitive factors include:

• Cost of Goods Sold (COGS): Efficiency in API synthesis and tablet manufacturing is paramount. Companies with vertically integrated supply chains or those able to source raw materials at lower costs have a competitive advantage.
• Scale of Production: Larger production volumes generally lead to lower per-unit costs.
• Distribution Channels: Access to major wholesalers, retail pharmacies, and government tenders is critical. Established relationships with these entities are a significant asset.
• Regulatory Compliance: Consistent adherence to GMP and successful navigation of regulatory inspections ensure uninterrupted supply and market access.
• Product Quality and Reliability: While bioequivalence is the standard, consistent product quality and a reliable supply chain build trust with prescribers and patients.

Pricing strategies for generic methyclothiazide are typically aggressive. Manufacturers aim to capture market share by offering the lowest possible price, often through bidding processes for large contracts or by competing directly with other generics on pharmacy shelves. Prices can vary significantly based on the supplier, the quantity purchased, and the specific market.

For example, a typical 30-count bottle of 5 mg methyclothiazide tablets might retail for between $5 and $20 USD, depending on the pharmacy and insurance coverage. Bulk purchases by hospitals or large pharmacy chains would command significantly lower per-unit pricing. This low-price environment limits the profit margin for individual sales but relies on high sales volumes to generate revenue.

What are potential investment considerations and risks for methyclothiazide?

Investing in the methyclothiazide market requires a focus on operational efficiency and market access rather than novel product development. The primary considerations and risks are associated with generic pharmaceutical manufacturing and distribution.

Investment Considerations:

• Manufacturing Efficiency: Investment in optimized synthesis routes, high-yield processes, and automated tablet manufacturing can reduce COGS and improve profitability.
• Supply Chain Management: Securing reliable, cost-effective sources of API precursors and managing inventory effectively are crucial for maintaining consistent supply and competitive pricing.
• Market Access and Distribution Networks: Building and maintaining strong relationships with wholesalers, distributors, and pharmacy benefit managers (PBMs) is vital for securing sales channels.
• Combination Therapies: Investing in companies that develop or market fixed-dose combination products containing methyclothiazide alongside other antihypertensive agents can offer a more stable and potentially higher-margin revenue stream. These combinations can simplify patient regimens and improve adherence.
• Emerging Markets: Expanding presence in developing countries where healthcare access is growing and generic medications are preferred can provide incremental growth opportunities.

Investment Risks:

• Intense Price Competition: The generic nature of methyclothiazide leads to relentless price erosion, squeezing profit margins. This can be exacerbated by new entrants or aggressive pricing by established players.
• Regulatory Scrutiny and Compliance Costs: Maintaining GMP compliance and navigating evolving regulatory requirements can be costly and time-consuming. Any regulatory misstep can lead to significant financial penalties and market disruption.
• Supply Chain Disruptions: Geopolitical events, raw material shortages, or manufacturing issues at key API suppliers can disrupt production and impact revenue.
• Therapeutic Obsolescence: While unlikely in the short term for a widely used drug like methyclothiazide, long-term shifts in treatment guidelines or the development of significantly superior alternatives could diminish its use.
• Limited Innovation Potential: The lack of patent protection means opportunities for significant product innovation are minimal. Growth is primarily volume-driven rather than innovation-driven.
• Counterfeit Products: The low-value nature of generics can sometimes attract counterfeit operations, which can damage brand reputation and patient safety if not rigorously policed.

For investors, a stake in a company with a proven track record in efficient generic manufacturing, robust quality systems, and established distribution networks would be most relevant for this particular drug.

What is the future outlook for methyclothiazide?

The future outlook for methyclothiazide is one of sustained, albeit slow, market presence. Its established efficacy, low cost, and inclusion in hypertension treatment guidelines ensure continued demand. The drug is unlikely to be replaced by a singular new development in the near to medium term due to its fundamental role in diuretic therapy and its affordability.

Key drivers of its future outlook include:

• Aging Population and Hypertension Prevalence: The global rise in the elderly population and the persistent increase in hypertension rates worldwide will continue to create a steady demand for effective and affordable antihypertensive medications like methyclothiazide.
• Cost-Effectiveness in Healthcare Systems: As healthcare systems globally face cost pressures, the affordability of generic medications like methyclothiazide will remain a significant advantage. It is often a preferred choice for both public health programs and cost-conscious patients.
• Role in Combination Therapies: Methyclothiazide is likely to remain a component in various fixed-dose combination antihypertensive drugs. These combinations simplify patient regimens and improve adherence, thus sustaining the drug's utility. The development of new combination products, while not revolutionary, can solidify its market position.
• Market Penetration in Developing Regions: Further expansion of healthcare infrastructure and access to essential medicines in emerging markets will likely drive incremental volume growth for established generics.

Challenges that may temper its growth include:

• Competition from Newer Drug Classes: While methyclothiazide remains a staple, newer classes of antihypertensives with different mechanisms of action and potentially better tolerability profiles for specific patient subsets will continue to compete for market share.
• Evolving Treatment Guidelines: While generally stable, treatment guidelines can evolve based on new research, potentially favoring other drug classes or combinations for certain patient profiles.
• Consolidation in the Generic Industry: Further consolidation among generic manufacturers could lead to increased pricing power for larger entities, but also potentially reduce the number of independent suppliers.

Overall, methyclothiazide is expected to remain a relevant therapeutic option and a stable product in the generic pharmaceutical market. Its future is characterized by consistent demand, driven by its therapeutic benefits and economic advantages, rather than significant expansion or innovation. Companies focusing on efficient manufacturing, robust quality control, and broad distribution networks will likely continue to profit from its stable market position.

Key Takeaways

• Methyclothiazide is an off-patent thiazide diuretic with expired composition of matter patents, enabling widespread generic competition.
• Its primary indications are hypertension and edema, supported by decades of clinical evidence.
• The market is fragmented, with numerous generic manufacturers focused on cost efficiency and volume.
• Growth potential is modest, driven by increasing hypertension prevalence and emerging market penetration, but constrained by intense price competition and newer therapeutic alternatives.
• Regulatory compliance, particularly GMP, is critical for manufacturing and market access.
• Investment opportunities lie in manufacturing efficiency, supply chain optimization, and established distribution networks rather than product innovation.
• The future outlook for methyclothiazide is stable, driven by its affordability, efficacy, and role in combination therapies, particularly in a global context of rising hypertension and cost-conscious healthcare.

Frequently Asked Questions

What is the typical daily dosage of methyclothiazide for hypertension?

The typical starting dosage for methyclothiazide in the management of hypertension is 2.5 mg to 5 mg taken orally once daily. Dosage adjustments may be made by a healthcare professional based on patient response and tolerance, with maximum recommended doses rarely exceeding 10 mg daily.

Are there any significant contraindications for methyclothiazide?

Yes, methyclothiazide is contraindicated in patients with anuria (inability to produce urine), known hypersensitivity to thiazides or sulfonamide-derived drugs, and in those with severe renal impairment or hepatic coma.

What are the common side effects associated with methyclothiazide?

Common side effects include electrolyte imbalances (hypokalemia, hyponatremia), dizziness, lightheadedness, weakness, and increased urination. Less common but serious side effects can include hypotension, hyperglycemia, and gastrointestinal disturbances.

Can methyclothiazide be used safely during pregnancy?

Methyclothiazide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally not recommended as a first-line treatment for hypertension in pregnancy, and its use requires careful medical supervision due to potential risks.

What are some examples of other drugs commonly combined with methyclothiazide?

Methyclothiazide is frequently combined with other antihypertensive medications to achieve better blood pressure control. Common combinations include ACE inhibitors (e.g., lisinopril), angiotensin II receptor blockers (ARBs) (e.g., losartan), and beta-blockers (e.g., atenolol).

What is bioequivalence in the context of generic methyclothiazide?

Bioequivalence means that a generic drug is expected to have the same rate and extent of absorption as the reference listed drug (RLD), the brand-name drug. For generic methyclothiazide, this is demonstrated through studies showing similar pharmacokinetic profiles (e.g., plasma concentration over time) to the RLD.

Citations

[1] Grand View Research. (2023). Diuretics Market Share, Size, Trends, Analysis Report By Product, By Application, By Region, And Segment Forecasts, 2024 – 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/diuretics-market (Note: While this report covers the broader diuretics market, specific data for methyclothiazide is proprietary and not publicly available in this granular format. This citation represents typical market growth expectations for the broader class.)